Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Welcome Email

Send Welcome Email If selected, this user will receive an automated welcome email to the Marketplace Platform.

Send Welcome Email Again

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Bolus Insulin, GLP-1RA, Insulin Delivery, Other, Topics

July 28, 2025

Sciwind GLP-1RA Licensing Rumors; Lilly Completes Verve Acquisition; Adocia Ph3 Insulin Lispro Data

Here is a brief preview of this blast: Three cardiometabolic-related news items: Sciwind is reportedly in conversations with a US pharma company interested in licensing its Ph3 obesity asset, ecnoglutide (QW SC GLP-1RA; view article); Lilly announces it completed the acquisition of Verve Therapeutics (view press release); and Adocia and Tonghua Dongbao announce Ph3 insulin lispro results in T2DM (view press release). Below, FENIX provides highlights and insights for the respective news items.